Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
Viruses · 2024
DOI: 10.3390/v16121889 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, 2024. Verfasst von Lauren Ogawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Foscarnet, Antiviral Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality. Treatment can be challenging due to medication-associated toxicities. Maribavir (MBV) is a promising option for the treatment of resistant or refractory (R/R) CMV infection in lieu of foscarnet (FOS), which has long been the recommended therapy for (val)ganciclovir-resistant infection. This was a single-center retrospective study of clinical outcomes of patients who received MBV compared to a control group who received FOS for an episode of CMV infection. Each cohort consisted of 27 episodes of CMV infection. Twenty patients in the MBV cohort and from the FOS cohort cleared the infection, with five and three patients developing MBV or FOS resistance, respectively. There were no statistically significant differences in failure of therapy as evidenced by persistent DNAemia (p = 0.56) or development of antiviral resistance (p = 0.24). In conclusion, MBV was as effective as FOS for the treatment of R/R CMV infection and was better tolerated without increased risk of antiviral resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
- Department of Pharmacy, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
ORCID-Profile: Lauren Ogawa, Chelsea Morinishi, Ashrit Multani, Omer E Beaird
Zitieren
APA
Ogawa, L., Morinishi, C., Multani, A., Gaynor, P., Beaird, O. E., Pham, C., & Schaenman, J. M. (2024). Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Viruses. https://doi.org/10.3390/v16121889
Vancouver
Ogawa L, Morinishi C, Multani A, Gaynor P, Beaird OE, Pham C, et al. Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Viruses. 2024. doi:10.3390/v16121889
BibTeX
@article{Ogawa2024,
author = {Ogawa, Lauren and Morinishi, Chelsea and Multani, Ashrit and Gaynor, Pryce and Beaird, Omer E and Pham, Christine and Schaenman, Joanna M},
title = {Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121889}
}
EUVIMED